CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
Colon Cancer|Pancreas Cancer|Digestive Cancer
DRUG: CEND-1|DRUG: Panitumumab|DRUG: Folfirinox
Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Adverse Events : Counts and proportions of grade 3 -5 Adverse Events, 24 months
Overall survival (OS), Overall survival (OS) will be reported using median survival time along with a 90% confidence interval, 48 months|Disease-free survival (DFS), Disease-free survival (DFS) will be reported using median survival time along with a 90% confidence interval, 48 months|Overall response rate (ORR), Overall response rate (ORR) will be reported as a proportion with 90% confidence interval., 24 months|RO resection rate (RORR), RO resection rate (RORR) will be reported as a proportion with 90% confidence interval., 24 months|Pathological response rate (PCR) ., Pathological response rate (PCR) will be reported as a proportion with 90% confidence interval., 24 months
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers